## Synthesis of 11-Deoxy- $10\alpha$ -hydroxyprostaglandins

By PIERRE CRABBÉ,\*† ALICIA CERVANTES, and M. CARMEN MEANA

(Research Laboratories, Syntex, S.A., Apartado Postal 10-820, Mexico 10, D.F., Mexico)

Summary The  $\beta$ -elimination of the 11-acetoxy-grouping of the aldehyde (2) by ready anion formation at C-12 gives the conjugated aldehyde (3); catalytic hydrogenation of (3), followed by alkylation under equilibrating conditions, allows access to novel prostaglandins, which are isomeric with  $PGF_{2\alpha}$  and  $PGE_{2}$ .

For some time we have been interested in the chemical synthesis of modified prostaglandins.<sup>1</sup> In particular, the preparation of several 11-deoxyprostaglandins,<sup>2</sup> and 10hydroxyprostaglandins<sup>3</sup> has been described. We now report the total synthesis of two new 11-deoxy-10-hydroxyprostaglandins.


This synthesis makes use of the ready elimination of acetate at C-11 by base treatment of the acetoxy-aldehyde (2), which provided the conjugated aldehyde (3). The alcohol (1b), m.p. 95–97°,  $\nu_{max}$  3400, 1770, 1740 cm<sup>-1</sup>,  $\ddagger$ readily prepared from (1a),<sup>1,3</sup> is oxidised with Collins' reagent<sup>4</sup> to afford the diacetoxy-aldehyde (2), which when treated with pyridine for several minutes, provides the conjugated aldehyde (3), m.p. 113°,  $\lambda_{max}$  227 nm ( $\epsilon$  4040), in 50% overall yield from (1b).

Catalytic hydrogenation of the double bond at C-11 with 5% Pd-C in dimethoxyethane solution yields quantitatively the saturated aldehyde (4). Alkylation of (4) with the sodium salt of dimethyl 2-oxoheptylphosphonate gives the expected enone (5),  $\lambda_{\max}$  224 nm ( $\epsilon$  12,600), in 68% yield. Zinc borohydride reduction of the carbonyl function at C-15 provides a mixture of 15(R)- and 15(S)-isomeric alcohols separated by preparative t.l.c. The desired 15(S)-alcohol (6a) is treated with methanolic  $K_2CO_3$  at room temperature, thus affording the corresponding 10,15diol (6b) in 95% yield. Treatment of (6b) with dihydropyran in the presence of a catalytic amount of acid gives almost quantitatively the 10,15-bis-ether (6c).

The concluding steps of the synthesis are shown in the Scheme. Reaction of the lactone group with di-isobutylaluminium hydride provides the lactol (7) (95%). This is then treated with 5-triphenylphosphoniopentanoic acid, to give the novel prostanoic acid as its bistetrahydropyranyl ether derivative (8a).

Hydrolysis of the  $10\alpha$ ,  $15\alpha$ -bis-ether (8a) with aqueous AcOH at room temperature, affords (±)-11-deoxy-10 $\alpha$ hydroxy-PGF<sub> $2\alpha$ </sub> (8b). Jones' oxidation<sup>5</sup> of (8a) provides the expected ketone (9a), which by exposure to aqueous AcOH affords (+)-11-deoxy-10 $\alpha$ -hydroxy-PGE<sub>2</sub> (9b).

A novel feature of this synthesis is the formation of the conjugated aldehyde which could be hydrogenated quantitatively to the saturated aldehyde (4). Although the configuration of the aldehyde group in (4) is probably  $12\alpha$ , equilibration occurs during the alkylation step, which



SCHEME

THP = tetrahydropyranyl Reagents: i,  $CrO_3$ ; ii, pyridine; iii,  $H_2$ , 5% Pd-C, DME; iv,  $C_5H_{11}$ - $C(O)\overline{C}HP(O)(OMe)_2$ , Na<sup>+</sup>, DME; v, a,  $Zn(BH_4)_2$ , b, t.l.c, c,

dihydropyran, TsOH; vi, Bu<sup>1</sup><sub>2</sub>AlH-C<sub>7</sub>H<sub>8</sub>, -70°; vii, Ph<sub>8</sub>PCH-[CH<sub>2</sub>]<sub>3</sub>CO<sub>2</sub>-, 2Na+, Me<sub>2</sub>SO.

† Present address: Laboratoire de Chimie Organique, C.E.R.M.O., Université Scientifique et Medicale, Boite Postale 53, 38.041, Grenoble, Cedex, France.

\$ Satisfactory elemental analyses or mass spectra were obtained for all new compounds. N.m.r. and i.r. spectra consistent with their formation.

provides the thermodynamically stable enone (5) with the desired  $\beta$ -configuration at C-12, as shown by its n.m.r. properties. This permitted the preparation of two novel prostaglandins in which the newly introduced hydroxygroup at C-10 $\alpha$  is in an isomeric position with respect to the natural 11-hydroxylated prostanoic acid derivatives. We thank Dr A. Guzmán for fruitful discussions.

(Received, 12th December 1972; Com. 2072.)

<sup>1</sup> P. Crabbé, Archiv. Invest. Médica (Mexico), 1972, 3, suppl. 1, 151; P. Crabbé, H. Carpio, and A. Guzmán, 'Proceedings on the Chemistry and Pharmacology of Prostaglandins,' Intra-Science Research Foundation, Santa Monica, California, 1972, 6, 55.
<sup>2</sup> P. Crabbé, and A. Guzmán, Tetrahedron Letters, 1972, 115; P. Crabbé, A. Cervantes, and A. Guzmán, Tetrahedron Letters, 1972, 1123.
<sup>3</sup> P. Crabbé, A. Guzmán, and E. Velarde, J.C.S. Chem. Comm., 1972, 1126.
<sup>4</sup> J. C. Collins, W. W. Hess, and F. J. Frank, Tetrahedron Letters, 1968, 3363.
<sup>5</sup> K. Bowden, I. M. Heilbron, E. R. H. Jones, and B. C. L. Weedon, J. Chem. Soc., 1945, 39.